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Abstract 
Purpose: To develop and optimize indomethacin (IDM) matrix tablets for specific colon drug delivery.  
Methods: Indomethacin matrix tablets containing hydrogenated castor oil (HCO), and pectin (PEC) 
were prepared by hot fusion method. A 32 full factorial design was used to investigate the combined 
effect of two independent formulation variables, X1 and X2, namely, the amount of HCO and PEC, 
respectively. Their effect on IDM release from the matrix tablets in acidic medium (0.1 N HCl) and 
phosphate buffer (pH 6.8), were analyzed and optimized. A contour plot was also applied to graphically 
represent the effect of the independent variables on drug release in pH 6.8 medium at 2 h (Y1) and 24 h 
(Y2), and the time required for 25 % drug release (Y3) as dependent variables.  
Results: The optimized IDM matrix tablets showed almost total retardation of drug release in acidic 
medium and prolonged sustained release in pH 6.8 medium over 24 h. The correlation coefficient (R2) 
value for Y1, Y2 and Y3 were 0.99850, 0.9980 and 0.9970, respectively, indicating good correlation 
between dependent and independent variables. Differences between the coefficients for Y1, Y2 and Y3 
were significant (p < 0.05), and hence contributed significantly to the prediction of the independent 
variables.  
Conclusion: The findings indicate that successful design, development, and optimization of IDM matrix 
tablets for colon delivery has been achieved. 
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Oral colon-specific drug delivery system (CDDS) 
has been developed as one of the site-specific 
drug delivery systems. This delivery system 
comprises a combination of one or more 
controlled release mechanisms leading to hardly 
any release of the drug in the upper part of the 
gastrointestinal (GI) tract, but rapid release in the 
colon following oral administration [1-3].  
 
Polysaccharides are widely used in oral drug 
delivery systems because of the simplicity to 
obtain the desired drug delivery system and drug 
release profile, by the control of cross-linking, 
insolubility of crosslinked beads in gastric 
environment and  broad regulatory acceptance 
[4-6]. The inability of the GIT enzymes to digest 
certain plant polysaccharides is taken advantage 
in developing a colon-specific drug delivery 
system. Various polysaccharides are being 
evaluated for colon targeting such as pectin 
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(PEC), guar gum, gum ghatti, dextran, chitosan, 
and xylan [7,8]. 
 
Indomethacin (IDM) is a nonsteroidal anti-
inflammatory drug (NSAID) that can exhibit 
chemoprotective effects against tumors and 
reduce the risk of colon cancer [9-11]. Despite 
recent advances in NSAIDs formulations, the 
design of targeted delivery systems to improve 
the efficacy and reduce side effects of NSAIDs 
continues to be a focus of much research [12-
14]. 
 
This study was aimed at the design and 
development of controlled release matrix tablets 
of IDM using hydrogenated castor oil (HCO) and 
PEC, with the aid of 32 full factorial design, to 







Indomethacin (γ- polymorphic form) (IDM) was 
kindly supplied by Pharco Pharmaceuticals, 
Alexandria, Egypt. Also used were pectin (PEC, 
BDH Co, England). hydrogenated castor oil 
(HCO, Girnar Industries, Gujarat, India, as well 
as talc and magnesium stearate (BDH Chemicals 
Ltd, Poole, UK). All other chemicals used were of 
reagent grade. 
 
Fourier transform infrared spectroscopy 
 
Fourier transform infrared (FTIR) spectrum of 
IDM and  physical mixtures (1:1:1) of  IDM with 
other excipients (PEC and HCO) as well as  
different formulations prepared by hot fusion 
method, namely F4 and F6, were performed to 
find out any possible drug- excipients interaction 
using KBr  pellet method using Perkin-Elmer 
FTIR series (model- 1615) spectrophotometer 
between 4000-450 cm-1. 
 
Preparation of indomethacin solid 
dispersions by hot fusion method 
 
Hydrogenated castor oil was melted in porcelain 
evaporating dish using a water bath at 60 °C. 
Indomethacin and pectin were mechanically 
mixed to form homogenous mixture and then this 
mixture was added with continuous stirring 
(HCO, PEC and the drug were used in the 
required ratios for each preparation) to get a 
homogeneous dispersion. The obtained molten 
mass was then allowed to cool down and solidify. 
Subsequently, the mass was ground, pulverized 
and passed through a 60-mesh sieve (< 300 
µm). The obtained powders were stored in 
desiccators at room temperature until use. 
 
Preparation of indomethacin matrix tablets 
 
The solid dispersion was directly compressed 
using a single punch tablet machine (Erweka, 
Germany) fitted with 9 mm diameter normal flat 
punches and die sets. Relatively constant tablet 
hardness was held around 10 kg. An amount of 
solid dispersion equivalent to 50 mg of IDM was 
compressed after the addition of 3 % w/w (of 
tablet weight) of lubricant (Talc: Magnesium 
stearate 9:1). Tablet weight was 300 ± 5 mg. 
Tablets were then subjected to in vitro release 
study. 
 
In vitro release studies 
 
The in vitro release study of IDM tablets was 
performed using USP apparatus II (Erweka, 
Germany) fitted with paddle (50 rpm) at 37 ± 0.5 
°C using 0.1 N HCl (pH 1.2, 900 mL) as a 
dissolution medium for the first 2 h, followed by 
pH 6.8 phosphate buffer solutions for further 10 
h. At the predetermined time intervals, 5 mL 
samples were withdrawn and replaced with fresh 
preheated dissolution medium, then the 
withdrawn samples were filtered through a 0.45 
μm membrane filter and assayed 
spectrophometrically at 270 nm using a UV 
spectrophotometer (Shimadzu, Kyoto, Japan). 
Cumulative drug release was computed from a 
standard calibration curve. The dissolution profile 
of all batches were fitted to various models 
including zero order, first order [15], Higuchi [16, 
17], Korsmeyer and Peppas [18] to ascertain the 
kinetics of drug release (Equations 1-4, 
respectively).  
 
C = K0t ………………………………….. (1) 
 
where, K0 is zero-order rate constant expressed 
in units of concentration/time and t is the time. 
 
Log C = LogC0 - K1t/2.303 …………… (2) 
 
where C0 is the initial concentration of drug and 
K1 is first order constant. 
 
Q = KHt1/2 ………………………………. (3) 
 
where, KH is the constant reflecting the design 
variables of the system.  
 
Mt/M∞ = Ktn ………..…………………… (4) 
 
where Mt/M∞ is fraction of drug released at time t, 
K is the release rate constant. 
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Optimization of variables using 32 full 
factorial design 
 
A 32 full factorial design was employed to 
systematically study the joint influence of the 
effect of independent variables X1 and X2 on the 
dependent variable. In this design, 2 factors were 
evaluated, each at 3 levels, and experimental 
trials were performed at all 9 possible 
combinations. The amounts of HCO (X1) and 
PEC (X2) were selected as independent 
variables in 32 full factorial design, while Y1, Y2 
and Y3 (% drug release after 2, 24 h and time 
required to release 25 % drug, respectively) were 
taken as dependent variables. The formulation 
layout for the factorial design batches (F1-F9) is 
shown in Table 1. 
 
Response surface analysis 
 
Two dimensional (2-D) contour plot and three 
dimensional (3-D) surface response plots where 
constructed based on the model polynomial 
function using Minitab program version 17. 
These plots are very useful to see interaction 




The results were analyzed by using Graph Pad 
software version 6. One way analysis of variance 
(ANOVA) with Tukey’s multiple comparisons post 
hoc was used to test for significant differences, 





Compatibility of IDM with the polymers 
 
Figure 1 demonstrates the characteristic IR 
peaks of pure IDM which were compared with 
peaks obtained from the respective physical 
mixture (1:1:1) as well as with F4 and F6. It was 
observed that characteristic peaks of IDM 
appears with identical or with minor differences, 
at frequencies 3370.33 and 1717.14 cm-1 
corresponding to carboxylic O−H and C=O 
stretch, respectively. The spectrum shows also 
characteristic peaks at 2961.65 cm–1 (C-H 
stretching vibrations), 1691.83 cm-1 (C = O 
stretching vibrations), 1234.15 cm-1 (asymmetric 
aromatic O-C stretching), 1086.55 cm-1 
(symmetric aromatic O-H stretching) and 
1479.50 cm-1 (C-C stretching) [19]. It can be 
seen that the peaks of the prepared formulations 
F4 and F6 as well as the physical mixture are the 
sum of the characteristic peaks of the drug and 
the corresponding excipients used. The spectra 
of Fig. 1 indicated the compatibility between the 
drug and the two polymers used for preparation 




In a preliminary study, batches containing 
various concentrations of HCO alone and in 
combination with the other polymer (PEC) were 
prepared to check their influence on in vitro 
characterization of compressed matrix tablets. It 
was found that as the concentration of HCO 
increased, the drug release for upper GIT was 
retarded till 6.79 %. It was found that tablets 
containing combinations of HCO with PEC 
retarded the drug release in pH 1.2 and gave 
faster drug release in pH 6.8. 
 
In vitro drug release 
 
Figure 2 illustrates the release profile of IDM 
from the different matrix tablets prepared by 
direct compression of the solid dispersion of the 
drug into the polymers. 
 
 
Table 1: Composition and the experimental design of factorial design batches 
   
Variable levels in coded form Dependent variables Batch code 
X1 X2 Y1 Y2 Y3 (T25%) 
F1 -1* -1** 0.78 76.00 50.00 
F2 -1 0** 0.98 66.20 47.32 
F3 -1 +1** 0.72 54.70 68.03 
F4 0* -1 1.20 70.00 39.60 
F5 0 0 2.00 59.27 71.00 
F6 0 +1 2.50 42.81 81.00 
F7 +1* -1 0.30 67.54 79.00 
F8 +1 0 0.30 55.86 42.00 
F9 +1 +1 0.00 41.43 40.00 
-1* 125 mg/tablet for X1, -1** 62.5 mg/tablet for X2;  0* 166.66 mg/tablet for X1, 0** 83.33 mg/tablet for X2; +1* 187.5 
mg/tablet for X1, +1** 125 mg/tablet for X2 
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Figure 1: IR spectra of indomethacin, pectin, hydrogenated castor oil, their physical mixture in the ratio of 1:1:1 
and after fusion (formulations F4 and F6) 
 
The release profile of IDM from the 9 batches 
showed drug release in pH 6.8 ranged from 0-2.5 
% after 2 h while,  drug release after 24 h ranged 
from 41 % to 76 %. The release of the drug after 
24 h for all the tablets prepared was based upon 
the mechanical mixtures of IDM and pectin. 
However, tablets prepared using high 
concentration of HCO (187.5 mg) showed IDM 
release of < 67 % after 24 h whereas, the tablets 
prepared with medium (166.66 mg) and low (125 
mg) concentrations of HCO released about 70 
and 76 % of the drug, respectively. As the 
amount of HCO increased from 125 mg (F1, F2 
and F3) to 187.5 mg (F7, F8 and F9), the drug 
release was significantly decreased (p < 0.05). 
The in vitro release profiles of drug from all these 
formulations can be best expressed by Higuchi 
equation as the correlation coefficient (R2) values 
were the highest (0.820 for F4 to 0.923 for F5) as 
compared with the other release kinetic models 
studied. 
 
Full factorial design 
 
According to the 32 factorial designs, various trial 
formulations of IDM matrix tablets were prepared 
by direct compression method using ingredients 
stated in Table 1. The results of the regression 
analysis indicated that these models were 
significant for all response parameters (Table 2). 
The minitab-17 program provided suitable 
polynomial model equations involving individual 
main factors and interaction factors after fitting 
these data. 
 
A statistical model incorporating interactive and 
polynomial terms was used to evaluate the 
response. 
 
Y= b0 + b1X1 + b2X2 + b3X1X2 + b4 X12 + b5X22 + 
b6X12X2  +b7X1X22 + b8X12X22 …………………… (5) 
 
where, Y is the dependent variable, b0 is the 
intercept representing the arithmetic mean 
response of the nine runs, and b1 is the 
estimated coefficient for the factor X1. The main 
effects (X1 and X2) represent the average result 
of changing one factor at a time from its low to 
high values. The interaction terms (X1X2) show 
how the response changes when 2 factors are 
simultaneously changed. The polynomial terms 
(X12 and X22) are included to investigate 
nonlinearity.  
 
The data from Fig 2 and data of Table 1 indicate 
that the drug release profile is strongly 
dependent on the selected independent 
variables. The fitted equations relating the 
responses, Y1, Y2 and Y3 to the transformed 
factor are shown in Table 2. 
 
The polynomial equations can be used to draw 
conclusions after considering the magnitude of 
coefficient and the mathematical sign it carries 
whether it is negative or positive. Table 2 shows 
the results of regression analysis which was 
performed to identify insignificant factors. Data 
were analyzed using Minitab 17 program.  
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Fig 2: Release profiles of (A) IDM matrix tablets F1, 
F2 and F3; (B) IDM matrix tablets F4, F5 and 
F6; (C) IDM matrix tablets F7, F8 and F9. Test 
performed in 0.1 N HCl for 2h and thereafter in 
phosphate buffer (pH 6.8) 
R2 value for Y1, Y2 and Y3 are 0.99850, 0.9980 
and 0.9970, respectively, indicating good 
correlation between dependent and independent 
variables. The significance levels of the 
coefficients in the Y1, Y2 and Y3 were found to 
be significant at p < 0.05 hence contribute 
significance information to the prediction of the 
independent variables. 
 
Factorial equation for Y1 
 
Y1 = 29.5992 - 0.84475 X1 - 13.0447 X2 
+ 2.64943 X1X2 + 13.4493 X12 + 8.1597 X22 
+ 11.6856 X12X2 - 2.67114 X1X22 -
 18.6842 X12X22 ……………… (6) 
 
Factorial equation for Y2 
 
Y2 = 59.2694 + 0.67001 X1 - 13.5987 X2 
+ 2.35862 X1X2 + 7.5979 X12 - 2.8694 X22 
+ 5.31173 X12X2 - 8.38236 X1X22 - 6.3578 X12X22 
………………. (7) 
 
Factorial equation for Y3 
 
Y3 = 70.9987- 2.65975 X1+ 20.6960 X2 -
 14.2558 X1X2 - 26.3390 X12 - 10.7008 X22 -
 25.9392 X12X2 + 2.89951 X1X22 
+ 25.3029 X12X22  ……………... (8) 
 
Response surface analysis 
 
Three-dimensional response surface plots and 
their corresponding contour plots to estimate the 
effects of the independent variables (factors) on 
each response investigated were presented in 
Fig. 3A, B and C. The three-dimensional 
response surface plots and corresponding 
contour plots relating drug release indicated the 
deceased values of Y1, Y2 and increased values 
of Y3 with the increment of the two independent 
variables X1 and X2 (amounts of HCO, and PEC 
in IDM matrix tablets). 
 
Table 2: Results of regression analysis 
 
 Y1  Y2  Y3  
 Coefficient P-value Coefficient   P-value Coefficient P-value 
Intercept 29.5992 0.0001 59.2694 0.000 70.9987 0.000 
X1 -0.84475 0.0002 0.67001 0.0001 -2.65975 0.0003 
X2 -13.0447 0.0001 -13.5987 0.0003 20.6960 0.0001 
X1X2 2.64943 0.0001 2.35862 0.000 -14.2558 0.0001 
X12 13.4493 0.0002 7.5979 0.0001 -26.3390 0.000 
X22 8.1597 0.0001 -2.8694 0.0003 -10.7008 0.0002 
X12X2 11.6856 0.0001 5.31173 0.0002 -25.9392 0.0001 
X1X22 -2.67114 0.0001 -8.38236 0.0001 2.89951 0.0001 
X12X22 -18.6842 0.0001 -6.3578 0.0001 25.3029 0.0001 
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Fig 3: Response surface and contour plots for drug release after (A) 2 h (Y1); (B) 24 h (Y2); and (C) for time 




The slower release from the solid dispersion 
matrices using HCO alone can be due to almost 
complete coating of the IDM particles by HCO 
melted in the process of hot fusion. Further 
batches were prepared using combinations of 
HCO and PEC to check the synergistic effect of 
various combinations on the drug release.  
 
On this preliminary study a factorial design was 
employed to find out the best combination of 
HCO and PEC that minimizes the further drug 
release in upper GIT and upon arrival to colon 
that releases the drug as quickly as possible. 
 
In vitro drug release 
 
It was expected that the penetration of the 
dissolution medium into the matrix will be low 
and hence, the release of the drug occurs at a 
slower rate. So, as the concentration of HCO 
increased the thickness of the drug particles 
coating increased leading to higher extent in drug 
release retardation.  
 
From Fig. 3 it was concluded that at higher 
percentage of PEC, the tablets could remain 
intact in the physiological environment of 
stomach and small intestine but once tablets 
enter into the colon, it is acted upon by 
polysaccharidases, which degrade the PEC and 
hence promote release the drug in the colon. 
 
The two criteria upon which the optimized 
formulations for colon delivery were selected are 
the percentage zero release in acidic medium 
(pH 1.2) and the slow release of the drug in pH 
6.8. Formulations F7, F8 and F9 fulfilled the 
previous two requirements. The slow release in 
vitro indicated reasonable release in vivo in 
presence of the pectinase enzyme. It was 
reported that the drug release in presence of rate 
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[20]. Consequently that 100 % drug release rate 
could be attained within 16 h, which is the normal 
residence time of a solid dosage form in the 
colon [21]. Therefore, it can be concluded that 
F7, F8 and F9 matrix tablets (Fig. 2C) would be 
considered as promising sustained release 
formulations of IDM for colon delivery. Higuchi’s 
kinetics explains why the drug diffuses at a 
comparatively slower rate (0.043 for F4 and 
0.083 for F6) as the distance for diffusion 
increases. All the formulations showed slope (n) 
values ranging from 0.494 for F4 to 0.618 for F6. 
The n values for all formulations indicated non-
Fickian diffusion which refers to a combination of 
both diffusion and erosion controlled-drug 
release. 
 
Traditionally, pharmaceutical formulators develop 
various formulations by changing one variable at 
a time but the method is time-consuming. 
However, many experiments not succeed in their 
purpose because they are not properly thought 
out and designed, and even the best data 
analysis cannot compensate lack of planning. 
Therefore, it is essential to understand the 
influence of formulation variables on the quality 
of formulations with a minimal number of 
experimental trials and subsequent selection of 
formulation variables to develop an optimized 
formulation using established statistical tools for 
optimization [22]. 
 
In case of Y1, the results of multiple regression 
analysis showed that both the coefficients b1 and 
b2 (coefficient of factors X1 and X2, respectively) 
bear a negative sign indicating a release 
retarding effect. It was anticipated that both 
matrix forming polymers would have synergistic 
retardant effect. The highly hydrophobic HCO 
and the gel forming polymer PEC ensured the 
expectation of very slow drug release rate. So 
increasing the amount of the two polymers in the 
formulation decreased the amount of drug 
released into the dissolution media. Depending 
on the value of the coefficient of factors, it can be 
stated that both polymers (X1 and X2) were 
responsible for the obtained value of Y1 but X2 
has more pronounced effect on drug release 
retardation. 
 
The amount of drug released after 24 h is an 
important parameter for prominent drug release 
from sustained release matrix formulation. The 
data of the factorial equation for Y2 showed that 
the coefficient factor of X2 is negative indicating a 
release retarding effect. The delay in drug 
release may be conditioned by the proportion of 
PEC in the formulations. As shown in Fig 2, as 
the amount of PEC increased in the tablet 
matrices, the drug release was decreased after 
24 h.  
 
The time required for 25 % drug release was 
selected for comparison between the different 
formulations. The coefficient factor of X1 is 
negative indicating that Y3 was strongly 
dependent on HCO as a matrix forming material. 
The time needed for melting of the hydrophobic 
polymer was the primary factor affecting the 
initial drug release. 
 
Response surface methodology is a widely 
proficient approach in the development and 
optimization of drug delivery devices [23,24]. The 
three-dimensional response surface plot is very 
useful in learning about the main and interaction 
effects of the independent variables (factors), 
whereas two-dimensional contour plot gives a 
visual representation of values of the response 
[23,24]. 
 
From the response surface analysis, it was found 
that the values decreased with the increase of 
two independent variables (amount of HCO and 
PEC). The higher viscosity due to increasing 
amount of hydrophilic polymer used, PEC may 
promote the formation of highly viscous gel upon 
contact with aqueous fluids of the dissolution 
medium, which would retard the drug release 




Indomethacin matrix tablets for colon delivery 
containing a combination of the polymers, HCO 
and PEC, hold good promise for drug release 
retardation. Successful 32 full factorial design, 
development, and optimization of IDM tablets 
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